<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539106</url>
  </required_header>
  <id_info>
    <org_study_id>intravitreal Ranibizumab reinj</org_study_id>
    <nct_id>NCT04539106</nct_id>
  </id_info>
  <brief_title>Intravitreal Ranibizumab in Recurrent ROP</brief_title>
  <official_title>Clinical Outcome Following Reinjection of Ranibizumab in Recurrent Cases With Retinopathy of Prematurity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ameera Gamal Abdelhameed</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A retrospective study included reviewing of medical records of preterm babies who were&#xD;
      admitted in neonatal intensive care unit (NICU) of Mansoura University children hospital&#xD;
      (MUCH) or referred from nearby hospitals for ROP screening during the period from March 2013&#xD;
      to February 2020.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retinopathy of prematurity was diagnosed and classified according to the International&#xD;
      Classification of ROP. Data of the patients who received IVR for type 1 ROP or aggressive&#xD;
      posterior ROP (AP-ROP) according to early treatment ROP study (ETROP) were collected.&#xD;
      Intravitreal ranibizumab injection was performed as follows; topical anesthetic drop was&#xD;
      applied, standard aseptic eye preparation with 5% betadine was performed, a lid speculum was&#xD;
      inserted and intravitreal injection of 0.25 mg/0.025 ml ranibizumab with a 30-gauge needle&#xD;
      1.5mm from limbus was given. In case of bilateral ROP, both eyes are injected in the same&#xD;
      session. Infants were examined a day after the procedure and weekly thereafter until full&#xD;
      vascularization of the retina was observed.&#xD;
&#xD;
      ROP reactivation was defined as any of the following: recurrent plus disease, recurrent&#xD;
      neovascularization, or reformation of ridge despite treatment . Once recurrence was&#xD;
      determined, second injection of IVR (0.25mg/0.025mL) was given to patients or surgery was&#xD;
      performed if progressed to stage 4 or 5. All treated infants were examined until complete&#xD;
      regression of ROP and full retinal vascularization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Actual">February 1, 2020</completion_date>
  <primary_completion_date type="Actual">February 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>full vascularization of the retina</measure>
    <time_frame>6 months</time_frame>
    <description>Infants were examined a day after the procedure and weekly thereafter until full vascularization of the retina was observed.</description>
  </primary_outcome>
  <enrollment type="Actual">115</enrollment>
  <condition>Retinopathy of Prematurity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravitreal injection of Ranibizumab</intervention_name>
    <description>intravitreal injection of 0.25 mg/0.025 ml ranibizumab with a 30-gauge needle 1.5mm from limbus</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ROP reactivation was defined as any of the following: recurrent plus disease, recurrent&#xD;
        neovascularization, or reformation of ridge despite treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients received IVR for type 1 ROP or aggressive posterior ROP (AP-ROP) according to&#xD;
             early treatment ROP study (ETROP) and developed recurrence of ROP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rania MR Bassiouny, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mansoura University</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Lad EM, Hernandez-Boussard T, Morton JM, Moshfeghi DM. Incidence of retinopathy of prematurity in the United States: 1997 through 2005. Am J Ophthalmol. 2009 Sep;148(3):451-8. doi: 10.1016/j.ajo.2009.04.018. Epub 2009 Jul 9.</citation>
    <PMID>19541285</PMID>
  </reference>
  <reference>
    <citation>Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008 Feb;84(2):77-82. doi: 10.1016/j.earlhumdev.2007.11.009. Epub 2008 Jan 29. Review.</citation>
    <PMID>18234457</PMID>
  </reference>
  <reference>
    <citation>Kwinta P, Bik-Multanowski M, Mitkowska Z, Tomasik T, Pietrzyk JJ. The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2008 Oct;246(10):1467-75. doi: 10.1007/s00417-008-0865-9. Epub 2008 Jun 11.</citation>
    <PMID>18546007</PMID>
  </reference>
  <reference>
    <citation>Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol. 1988 Apr;106(4):471-9.</citation>
    <PMID>2895630</PMID>
  </reference>
  <reference>
    <citation>McNamara JA, Tasman W, Brown GC, Federman JL. Laser photocoagulation for stage 3+ retinopathy of prematurity. Ophthalmology. 1991 May;98(5):576-80.</citation>
    <PMID>2062488</PMID>
  </reference>
  <reference>
    <citation>Hunter DG, Repka MX. Diode laser photocoagulation for threshold retinopathy of prematurity. A randomized study. Ophthalmology. 1993 Feb;100(2):238-44.</citation>
    <PMID>8437833</PMID>
  </reference>
  <reference>
    <citation>Iverson DA, Trese MT, Orgel IK, Williams GA. Laser photocoagulation for threshold retinopathy of prematurity. Arch Ophthalmol. 1991 Oct;109(10):1342-3.</citation>
    <PMID>1929909</PMID>
  </reference>
  <reference>
    <citation>Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011 Feb 17;364(7):603-15. doi: 10.1056/NEJMoa1007374.</citation>
    <PMID>21323540</PMID>
  </reference>
  <reference>
    <citation>Lin CJ, Chen SN, Tseng CC, Chang YC, Hwang JF. Effects of ranibizumab on very low birth weight infants with stage 3 retinopathy of prematurity: A preliminary report. Taiwan Journal of Ophthalmology 2012; 2: 136-139</citation>
  </reference>
  <reference>
    <citation>Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007 Dec;114(12):2179-82.</citation>
    <PMID>18054637</PMID>
  </reference>
  <reference>
    <citation>Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012 Oct;154(4):682-686.e2. doi: 10.1016/j.ajo.2012.03.047. Epub 2012 Jul 19.</citation>
    <PMID>22818800</PMID>
  </reference>
  <reference>
    <citation>Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007 May;114(5):855-9.</citation>
    <PMID>17467524</PMID>
  </reference>
  <reference>
    <citation>Mireskandari K, Adams GG, Tehrani NN. Recurrence of retinopathy of prematurity following bevacizumab monotherapy: is it only the tip of the iceberg? JAMA Ophthalmol. 2013 Apr;131(4):544-5. doi: 10.1001/jamaophthalmol.2013.711.</citation>
    <PMID>23579608</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Ameera Gamal Abdelhameed</investigator_full_name>
    <investigator_title>Lecturer of Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

